Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.

Anhedonia, a core symptom of depression, correlates with motor alterations in major depressive disorder and has been assumed to be frequent in depressed patients with Parkinson's disease (PD). In the present study, the authors assessed for the first time frequency of anhedonia in patients with idiopathic Parkinson's disease (N = 657) and the relationship of anhedonia and parkinsonian motor deficits during treatment with pramipexole. Mild depression was present in 47% of the patients and moderate to severe depression in 22%. Anhedonic individuals included 45.7% of all patients and 79.7% of depressed Parkinson's disease patients. Anhedonic Parkinson's disease patients had greater motor deficits, restrictions in activities of daily living, and depression compared to nonanhedonic patients. Frequency of anhedonia and depression was significantly reduced during treatment with pramipexole. Future studies should further investigate antianhedonic efficacy of dopamine agonists including pramipexole in depressed patients with Parkinson's disease.

[1]  D. Brooks,et al.  Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. , 1997, Clinical neuropharmacology.

[2]  J. Saint-Cyr,et al.  Depression in Parkinson's disease: reconciling physiological and psychological perspectives. , 1990, The Journal of neuropsychiatry and clinical neurosciences.

[3]  H. Mayberg,et al.  Depression in Parkinson's disease: a biochemical and organic viewpoint. , 1995, Advances in neurology.

[4]  A. Heinz,et al.  Anhedonia in Schizophrenic, Depressed, or Alcohol-Dependent Patients - Neurobiological Correlates , 1994, Pharmacopsychiatry.

[5]  Dwight L. Evans,et al.  Comparison of pramipexole, fluoxetine, and placebo in patients with major depression , 2000, Depression and anxiety.

[6]  Marjan Jahanshahi,et al.  What contributes to quality of life in patients with Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[7]  M. Hamilton,et al.  A Scale for the Assessment of Hedonic Tone the Snaith–Hamilton Pleasure Scale , 1995, British Journal of Psychiatry.

[8]  R. Snaith,et al.  Deutsche Version der Snaith-Hamilton-Pleasure-Scale (SHAPS-D) , 1998 .

[9]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[10]  H Helenius,et al.  The quality of life in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[12]  P. Willner,et al.  Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole , 1994, Psychopharmacology.

[13]  R. Snaith.  Identifying depression: the significance of anhedonia. , 1993, Hospital practice.

[14]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[15]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[16]  Mitsutoshi Yamamoto.  Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background , 2001, Journal of Neurology.

[17]  G. Skuza,et al.  The behavioural effects of pramipexole, a novel dopamine receptor agonist. , 1997, European journal of pharmacology.

[18]  A. Heinz,et al.  Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. , 1996, Archives of general psychiatry.

[19]  Roger Kurlan,et al.  A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.

[20]  T. Winkler,et al.  Psychomotor retardation and anhedonia in depression , 1999, Acta psychiatrica Scandinavica.

[21]  H. Braak,et al.  Pathoanatomy of Parkinson’s disease , 2000, Journal of Neurology.